Beam Therapeutics Inc. Earnings Per Share, Basic and Diluted
Beam Therapeutics Inc. (BEAM) reported Earnings Per Share, Basic and Diluted of -$3.35 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-11
- Beam Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$3.35.
- Beam Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$1.69.
- Beam Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.69.
- Beam Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.69.
- Beam Therapeutics Inc. earnings per share, basic and diluted for fiscal 2020 was -$4.19.
- Beam Therapeutics Inc. earnings per share, basic and diluted for fiscal 2019 was -$14.05.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$3.35 10-Q · filed 2021-05-11 | -$5.08 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$5.96 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$6.76 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$1.69 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.44 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.15 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$4.19 10-K · filed 2021-03-15 |
| 2020-09-30 | -$0.69 10-Q · filed 2020-11-10 | -$1.38 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.31 10-Q · filed 2020-11-10 | -$3.83 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-06-30 | -$0.69 10-Q · filed 2020-08-12 | -$1.65 10-Q · filed 2020-08-12 | -$3.34 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$5.08 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-03-31 | -$1.03 10-Q · filed 2021-05-11 | -$3.32 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$5.73 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$8.36 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2019-12-31 | -$4.35 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$7.69 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$11.11 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$14.05 10-K · filed 2021-03-15 |
| 2019-09-30 | -$3.31 10-Q · filed 2020-11-10 | -$6.69 derived: net income ÷ weighted average shares · filed 2020-11-10 | -$9.58 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$3.38 10-Q · filed 2020-08-12 | -$6.26 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$2.86 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |